ConductScience.org, home

Paper31056705

URC102, a potent and selective inhibitor of hURAT1, reduced serum uric acid in healthy volunteers.

Lee HA and 6 others. Rheumatology (Oxford), 2019. Cited by 17 papers, by iCite.

Cite this record

ConductScience Library. URC102, a potent and selective inhibitor of hURAT1, reduced serum uric acid in healthy volunteers. Papers, record 31056705. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31056705

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
URC102, a potent and selective inhibitor of hURAT1, reduced serum uric acid in healthy volunteers.
PubMed
Journal
Rheumatology (Oxford)
PubMed
Year
2019
PubMed
Publication types
Clinical Trial, Phase I, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
17
iCite
Relative citation ratio, by iCite
1.05
iCite
Revised in PubMed
2022-12-07
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Lee HAHyun A
2Yu KSKyung-Sang
3Park SISang-In
4Yoon SSeonghae
5Onohara MMakoto
6Ahn YYoungjoo
7Lee HHoward

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Hydrocarbons, BrominatedMajor topic
Organic Anion TransportersMajor topic
Organic Cation Transport ProteinsMajor topic
Uric AcidMajor topic
Uricosuric AgentsMajor topic
Administration, Oral
Adult
Asian People
Double-Blind Method
Gout
Healthy Volunteers
Humans
Hyperuricemia
Male
White People

Source PubMed

Download CSV of topics

Trials4

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT01953497Phase 1 Study of URC102 in Healthy SubjectsDerived from the trialYesClinicalTrials.gov
NCT02524678Phase 1 Study(Additional) of URC102 in Healthy SubjectsDerived from the trialYesClinicalTrials.gov
NCT07324434A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral F-02-2-Na Tablets in Adult SubjectsBackgroundClinicalTrials.gov
NCT07346027Safety and Food Effect on Single-Dose Bioavailability of F-02-2-Na in Healthy Adult SubjectsBackgroundClinicalTrials.gov

Download CSV of trials

Cited by11

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 17 citations.

PMIDTitleJournalYearIn PapersSource
42542893The Dual Role of Uric Acid: Pathological Implications Across Chronic Diseases and Current Approaches to Hyperuricemia Management.Discoveries (Craiova)2026https://conductscience.org/library/papers/42542893PubMed
41753671Serum Uric Acid-Reducing Effect and Intestinal Mucosal Barrier-Repairing Function of Limosilactobacillus reuteri MBHC10138.Microorganisms2026https://conductscience.org/library/papers/41753671PubMed
41340907Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effects of Single and Multiple Oral Doses of ABP-671 in Healthy and Hyperuricemic Subjects.Drug Des Devel Ther2025https://conductscience.org/library/papers/41340907PubMed
41065961URAT1 and GLUT9 as drug targets in gout: progress in transporter-directed therapies and delivery technologies.Inflammopharmacology2025https://conductscience.org/library/papers/41065961PubMed
40513003Impact of Renal Impairment on the Pharmacodynamic and Pharmacokinetic Profiles of Epaminurad, a Novel Uric Acid Transporter 1 Inhibitor.Clin Transl Sci2025https://conductscience.org/library/papers/40513003PubMed
40420308Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study.Arthritis Res Ther2025https://conductscience.org/library/papers/40420308PubMed
39385411From Patents to Progress: Unraveling Gout's Journey Through Clinical Trials and Advancements.Rev Recent Clin Trials2025https://conductscience.org/library/papers/39385411PubMed
37819612Emerging Urate-Lowering Drugs and Pharmacologic Treatment Strategies for Gout: A Narrative Review.Drugs2023https://conductscience.org/library/papers/37819612PubMed
36081938Review of Urate-Lowering Therapeutics: From the Past to the Future.Front Pharmacol2022https://conductscience.org/library/papers/36081938PubMed
34204277Modulation of Urate Transport by Drugs.Pharmaceutics2021https://conductscience.org/library/papers/34204277PubMed
33568990The Efficacy and Mechanism of Chinese Herbal Medicines in Lowering Serum Uric Acid Levels: A Systematic Review.Front Pharmacol2020https://conductscience.org/library/papers/33568990PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
SLC22A12116085PubTator's text mininghttps://conductscience.org/library/genes/116085

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/31056705

GET https://conductscience.org/api/papers/v1/31056705/authors